Vivo Capital and ZQ Capital to acquire Angiotech Pharmaceuticals

Angiotech Pharmaceuticals entered into a definitive agreement to be acquired by an investor group led by Vivo Capital and ZQ Capital, including GSO Capital Partners and others. Terms were not disclosed.

“Angiotech Pharmaceuticals (Canada) today announced that it has entered into a definitive agreement to be acquired by a group of investors led by Vivo Capital LLC and ZQ Capital Limited.”prnewswire.com

• 1 source
• prnewswire.comVivo Capital and ZQ Capital Limited enter into an Agreement to Acquire Angiotech PharmaceuticalsVivo CapitalDec 19, 2016

Summarized from public sources; check the original articles before acting on it.